Prevention of stent thrombosis with reduced dose of prasugrel in two patients undergoing treatment of cerebral aneurysms with pipeline embolisation devices

G. Morgan Jones, Jennifer D. Twilla, Daniel A. Hoit, Adam Arthur

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Prevention of intracranial stent thrombosis with dual-antiplatelet therapy is widely used in neuroendovascular procedures. However, the rising incidence of inadequate platelet inhibition with clopidogrel may increase complications following stent placement, especially with newer devices that possess a larger total metal surface area. While there are recent reports of prasugrel as an alternative to clopidogrel, there is no clinical evidence in neurointerventional patients regarding the use of a lower maintenance dose as an alternative strategy to gain adequate platelet inhibition while possibly reducing the risk of bleeding. We present 6-month efficacy and safety outcomes of two patients undergoing elective pipeline embolisation that were found to have inadequate platelet response to clopidogrel and subsequently transitioned to prasugrel 5 mg daily for the prevention of stent thrombosis.

Original languageEnglish (US)
JournalBMJ Case Reports
DOIs
StatePublished - Jan 1 2012

Fingerprint

clopidogrel
Intracranial Aneurysm
Stents
Thrombosis
Blood Platelets
Equipment and Supplies
Intracranial Thrombosis
Therapeutics
Metals
Hemorrhage
Safety
Incidence
Prasugrel Hydrochloride

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Prevention of stent thrombosis with reduced dose of prasugrel in two patients undergoing treatment of cerebral aneurysms with pipeline embolisation devices. / Jones, G. Morgan; Twilla, Jennifer D.; Hoit, Daniel A.; Arthur, Adam.

In: BMJ Case Reports, 01.01.2012.

Research output: Contribution to journalArticle

@article{92611e6a5e1f49a0a6829350f739db2f,
title = "Prevention of stent thrombosis with reduced dose of prasugrel in two patients undergoing treatment of cerebral aneurysms with pipeline embolisation devices",
abstract = "Prevention of intracranial stent thrombosis with dual-antiplatelet therapy is widely used in neuroendovascular procedures. However, the rising incidence of inadequate platelet inhibition with clopidogrel may increase complications following stent placement, especially with newer devices that possess a larger total metal surface area. While there are recent reports of prasugrel as an alternative to clopidogrel, there is no clinical evidence in neurointerventional patients regarding the use of a lower maintenance dose as an alternative strategy to gain adequate platelet inhibition while possibly reducing the risk of bleeding. We present 6-month efficacy and safety outcomes of two patients undergoing elective pipeline embolisation that were found to have inadequate platelet response to clopidogrel and subsequently transitioned to prasugrel 5 mg daily for the prevention of stent thrombosis.",
author = "Jones, {G. Morgan} and Twilla, {Jennifer D.} and Hoit, {Daniel A.} and Adam Arthur",
year = "2012",
month = "1",
day = "1",
doi = "10.1136/bcr-2012-010482",
language = "English (US)",
journal = "BMJ Case Reports",
issn = "1757-790X",
publisher = "BMJ Publishing Group",

}

TY - JOUR

T1 - Prevention of stent thrombosis with reduced dose of prasugrel in two patients undergoing treatment of cerebral aneurysms with pipeline embolisation devices

AU - Jones, G. Morgan

AU - Twilla, Jennifer D.

AU - Hoit, Daniel A.

AU - Arthur, Adam

PY - 2012/1/1

Y1 - 2012/1/1

N2 - Prevention of intracranial stent thrombosis with dual-antiplatelet therapy is widely used in neuroendovascular procedures. However, the rising incidence of inadequate platelet inhibition with clopidogrel may increase complications following stent placement, especially with newer devices that possess a larger total metal surface area. While there are recent reports of prasugrel as an alternative to clopidogrel, there is no clinical evidence in neurointerventional patients regarding the use of a lower maintenance dose as an alternative strategy to gain adequate platelet inhibition while possibly reducing the risk of bleeding. We present 6-month efficacy and safety outcomes of two patients undergoing elective pipeline embolisation that were found to have inadequate platelet response to clopidogrel and subsequently transitioned to prasugrel 5 mg daily for the prevention of stent thrombosis.

AB - Prevention of intracranial stent thrombosis with dual-antiplatelet therapy is widely used in neuroendovascular procedures. However, the rising incidence of inadequate platelet inhibition with clopidogrel may increase complications following stent placement, especially with newer devices that possess a larger total metal surface area. While there are recent reports of prasugrel as an alternative to clopidogrel, there is no clinical evidence in neurointerventional patients regarding the use of a lower maintenance dose as an alternative strategy to gain adequate platelet inhibition while possibly reducing the risk of bleeding. We present 6-month efficacy and safety outcomes of two patients undergoing elective pipeline embolisation that were found to have inadequate platelet response to clopidogrel and subsequently transitioned to prasugrel 5 mg daily for the prevention of stent thrombosis.

UR - http://www.scopus.com/inward/record.url?scp=84872161782&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872161782&partnerID=8YFLogxK

U2 - 10.1136/bcr-2012-010482

DO - 10.1136/bcr-2012-010482

M3 - Article

JO - BMJ Case Reports

JF - BMJ Case Reports

SN - 1757-790X

ER -